Concepts (325)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognition | 47 | 2023 | 1270 | 7.970 |
Why?
|
| Brain | 38 | 2023 | 1543 | 4.950 |
Why?
|
| White Matter | 11 | 2022 | 123 | 4.730 |
Why?
|
| Aging | 35 | 2023 | 1458 | 4.630 |
Why?
|
| Cognitive Dysfunction | 31 | 2023 | 1005 | 3.930 |
Why?
|
| Aged | 114 | 2023 | 8448 | 3.830 |
Why?
|
| Neuropsychological Tests | 59 | 2023 | 1141 | 3.510 |
Why?
|
| Alzheimer Disease | 29 | 2023 | 2026 | 3.480 |
Why?
|
| Cardiovascular Diseases | 13 | 2023 | 301 | 3.440 |
Why?
|
| Diffusion Tensor Imaging | 12 | 2023 | 57 | 2.770 |
Why?
|
| Magnetic Resonance Imaging | 34 | 2023 | 1032 | 2.750 |
Why?
|
| Humans | 140 | 2023 | 25165 | 2.680 |
Why?
|
| Cognition Disorders | 17 | 2020 | 943 | 2.600 |
Why?
|
| Female | 99 | 2023 | 14161 | 2.590 |
Why?
|
| Male | 96 | 2023 | 13815 | 2.540 |
Why?
|
| Hypertension | 7 | 2022 | 177 | 2.450 |
Why?
|
| Depression | 8 | 2020 | 428 | 2.260 |
Why?
|
| Middle Aged | 68 | 2023 | 8303 | 2.120 |
Why?
|
| Executive Function | 20 | 2023 | 106 | 2.120 |
Why?
|
| Blood Pressure | 8 | 2022 | 186 | 1.970 |
Why?
|
| Aged, 80 and over | 51 | 2023 | 4508 | 1.890 |
Why?
|
| Dementia | 16 | 2023 | 532 | 1.810 |
Why?
|
| Verbal Learning | 10 | 2021 | 32 | 1.790 |
Why?
|
| Acculturation | 3 | 2023 | 31 | 1.740 |
Why?
|
| Memory, Short-Term | 11 | 2023 | 92 | 1.710 |
Why?
|
| Diet, Mediterranean | 5 | 2023 | 99 | 1.700 |
Why?
|
| Connectome | 5 | 2021 | 11 | 1.690 |
Why?
|
| Risk Factors | 26 | 2023 | 2179 | 1.640 |
Why?
|
| Gray Matter | 5 | 2023 | 48 | 1.560 |
Why?
|
| Prefrontal Cortex | 7 | 2016 | 131 | 1.540 |
Why?
|
| Health Literacy | 3 | 2023 | 96 | 1.460 |
Why?
|
| Neuroimaging | 9 | 2022 | 118 | 1.440 |
Why?
|
| Cerebrovascular Disorders | 4 | 2021 | 123 | 1.380 |
Why?
|
| Memory Disorders | 5 | 2018 | 153 | 1.330 |
Why?
|
| Residence Characteristics | 4 | 2021 | 200 | 1.310 |
Why?
|
| Decision Making | 6 | 2023 | 202 | 1.280 |
Why?
|
| Arteriolosclerosis | 3 | 2023 | 72 | 1.180 |
Why?
|
| Public Health | 6 | 2021 | 64 | 1.170 |
Why?
|
| Brain Mapping | 9 | 2021 | 141 | 1.160 |
Why?
|
| United States | 18 | 2021 | 1928 | 1.100 |
Why?
|
| Mental Status and Dementia Tests | 4 | 2021 | 54 | 1.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 153 | 1.040 |
Why?
|
| Depressive Disorder | 5 | 2017 | 174 | 1.040 |
Why?
|
| Cohort Studies | 18 | 2023 | 1772 | 1.030 |
Why?
|
| Nerve Fibers, Myelinated | 5 | 2013 | 28 | 1.020 |
Why?
|
| Depressive Disorder, Major | 9 | 2018 | 100 | 1.010 |
Why?
|
| Memory | 10 | 2021 | 286 | 1.000 |
Why?
|
| Apolipoproteins E | 4 | 2023 | 243 | 0.980 |
Why?
|
| Stroke | 5 | 2023 | 245 | 0.950 |
Why?
|
| Exercise | 7 | 2022 | 429 | 0.950 |
Why?
|
| Cognitive Aging | 3 | 2020 | 73 | 0.940 |
Why?
|
| Cross-Sectional Studies | 14 | 2023 | 852 | 0.940 |
Why?
|
| Hippocampus | 9 | 2022 | 260 | 0.920 |
Why?
|
| Educational Status | 5 | 2023 | 273 | 0.900 |
Why?
|
| Psychomotor Performance | 9 | 2020 | 191 | 0.900 |
Why?
|
| Tryptophan | 4 | 2012 | 9 | 0.890 |
Why?
|
| Pattern Recognition, Visual | 2 | 2019 | 18 | 0.880 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 123 | 0.880 |
Why?
|
| Linear Models | 6 | 2020 | 238 | 0.850 |
Why?
|
| Spatial Processing | 2 | 2021 | 6 | 0.850 |
Why?
|
| Mental Recall | 7 | 2020 | 61 | 0.820 |
Why?
|
| Adult | 25 | 2023 | 7259 | 0.820 |
Why?
|
| Income | 3 | 2021 | 77 | 0.810 |
Why?
|
| Genotype | 5 | 2020 | 338 | 0.800 |
Why?
|
| Social Participation | 1 | 2022 | 12 | 0.790 |
Why?
|
| Blood Glucose | 2 | 2022 | 97 | 0.780 |
Why?
|
| Crime Victims | 1 | 2022 | 30 | 0.770 |
Why?
|
| Clinical Protocols | 1 | 2022 | 56 | 0.760 |
Why?
|
| Anisotropy | 5 | 2023 | 43 | 0.750 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2018 | 149 | 0.740 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 40 | 0.740 |
Why?
|
| Cerebral Cortex | 4 | 2021 | 146 | 0.730 |
Why?
|
| Psychology | 1 | 2021 | 21 | 0.720 |
Why?
|
| Optimism | 1 | 2021 | 2 | 0.720 |
Why?
|
| Longitudinal Studies | 12 | 2023 | 1301 | 0.720 |
Why?
|
| Family Relations | 1 | 2021 | 13 | 0.710 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 54 | 0.700 |
Why?
|
| Social Segregation | 1 | 2020 | 6 | 0.700 |
Why?
|
| Social Environment | 1 | 2021 | 73 | 0.700 |
Why?
|
| Dementia, Vascular | 5 | 2020 | 42 | 0.690 |
Why?
|
| Racism | 1 | 2021 | 29 | 0.690 |
Why?
|
| Cholesterol | 2 | 2019 | 58 | 0.680 |
Why?
|
| Social Capital | 1 | 2020 | 2 | 0.670 |
Why?
|
| Loneliness | 1 | 2021 | 59 | 0.670 |
Why?
|
| Analysis of Variance | 9 | 2017 | 241 | 0.670 |
Why?
|
| Dyslipidemias | 1 | 2019 | 15 | 0.650 |
Why?
|
| Triglycerides | 1 | 2019 | 57 | 0.650 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 38 | 0.650 |
Why?
|
| Social Support | 1 | 2021 | 191 | 0.640 |
Why?
|
| Life Style | 1 | 2021 | 180 | 0.640 |
Why?
|
| Hyperinsulinism | 1 | 2019 | 4 | 0.630 |
Why?
|
| Prospective Studies | 13 | 2022 | 1618 | 0.630 |
Why?
|
| Mental Processes | 1 | 2019 | 14 | 0.630 |
Why?
|
| Cultural Diversity | 1 | 2019 | 20 | 0.620 |
Why?
|
| Insulin Resistance | 1 | 2019 | 45 | 0.610 |
Why?
|
| Neural Pathways | 9 | 2018 | 60 | 0.610 |
Why?
|
| Community Health Services | 1 | 2019 | 33 | 0.610 |
Why?
|
| Independent Living | 6 | 2022 | 298 | 0.610 |
Why?
|
| Stress, Psychological | 1 | 2021 | 229 | 0.610 |
Why?
|
| Multilingualism | 1 | 2019 | 21 | 0.610 |
Why?
|
| Phenotype | 2 | 2019 | 286 | 0.600 |
Why?
|
| Kidney | 1 | 2019 | 145 | 0.600 |
Why?
|
| Psychological Trauma | 1 | 2017 | 4 | 0.560 |
Why?
|
| Affect | 3 | 2013 | 57 | 0.540 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 370 | 0.530 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 40 | 0.530 |
Why?
|
| Individuality | 1 | 2016 | 19 | 0.510 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2023 | 155 | 0.500 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 5 | 0.480 |
Why?
|
| Thinking | 1 | 2014 | 14 | 0.460 |
Why?
|
| Psychomotor Disorders | 1 | 2014 | 10 | 0.460 |
Why?
|
| Verbal Behavior | 5 | 2009 | 16 | 0.460 |
Why?
|
| Obesity | 4 | 2023 | 291 | 0.450 |
Why?
|
| Sex Factors | 6 | 2020 | 430 | 0.450 |
Why?
|
| Age Factors | 8 | 2020 | 712 | 0.450 |
Why?
|
| Surveys and Questionnaires | 9 | 2021 | 1085 | 0.430 |
Why?
|
| Vascular Diseases | 2 | 2013 | 40 | 0.430 |
Why?
|
| Memory, Episodic | 3 | 2018 | 105 | 0.420 |
Why?
|
| Serotonin | 3 | 2012 | 23 | 0.410 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2012 | 32 | 0.400 |
Why?
|
| Health Surveys | 4 | 2021 | 82 | 0.400 |
Why?
|
| Leukoaraiosis | 2 | 2012 | 7 | 0.400 |
Why?
|
| Attention | 6 | 2023 | 116 | 0.400 |
Why?
|
| Alleles | 4 | 2023 | 211 | 0.400 |
Why?
|
| Models, Statistical | 3 | 2021 | 125 | 0.390 |
Why?
|
| Galvanic Skin Response | 1 | 2011 | 7 | 0.380 |
Why?
|
| Gambling | 1 | 2011 | 8 | 0.380 |
Why?
|
| Case-Control Studies | 9 | 2023 | 557 | 0.380 |
Why?
|
| Models, Psychological | 1 | 2011 | 68 | 0.370 |
Why?
|
| Dancing | 2 | 2021 | 13 | 0.370 |
Why?
|
| Biomarkers | 4 | 2021 | 520 | 0.370 |
Why?
|
| Down Syndrome | 1 | 2011 | 9 | 0.370 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2023 | 138 | 0.360 |
Why?
|
| Brain Chemistry | 1 | 2011 | 42 | 0.360 |
Why?
|
| Frontal Lobe | 4 | 2018 | 77 | 0.360 |
Why?
|
| Crime | 2 | 2021 | 7 | 0.350 |
Why?
|
| Basal Ganglia Cerebrovascular Disease | 1 | 2010 | 3 | 0.340 |
Why?
|
| Sex Characteristics | 2 | 2022 | 112 | 0.330 |
Why?
|
| Chicago | 3 | 2021 | 916 | 0.330 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2016 | 174 | 0.330 |
Why?
|
| Apolipoprotein E4 | 3 | 2020 | 255 | 0.300 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2017 | 301 | 0.300 |
Why?
|
| Neural Inhibition | 1 | 2007 | 6 | 0.290 |
Why?
|
| Myelin Sheath | 2 | 2021 | 21 | 0.290 |
Why?
|
| Amnesia | 5 | 2020 | 23 | 0.280 |
Why?
|
| Learning | 2 | 2018 | 66 | 0.270 |
Why?
|
| Self Report | 3 | 2023 | 212 | 0.270 |
Why?
|
| Hospitalization | 2 | 2019 | 284 | 0.270 |
Why?
|
| Principal Component Analysis | 3 | 2021 | 23 | 0.260 |
Why?
|
| Language | 3 | 2021 | 61 | 0.260 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 641 | 0.260 |
Why?
|
| Nerve Net | 5 | 2018 | 37 | 0.260 |
Why?
|
| Prevalence | 4 | 2021 | 428 | 0.260 |
Why?
|
| Pilot Projects | 3 | 2022 | 390 | 0.260 |
Why?
|
| DNA-Binding Proteins | 3 | 2023 | 250 | 0.250 |
Why?
|
| Problem Solving | 2 | 2009 | 37 | 0.240 |
Why?
|
| Young Adult | 5 | 2021 | 1813 | 0.230 |
Why?
|
| Temporal Lobe | 3 | 2018 | 76 | 0.230 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 836 | 0.230 |
Why?
|
| Discrimination Learning | 1 | 2004 | 1 | 0.230 |
Why?
|
| Color Perception | 1 | 2004 | 5 | 0.230 |
Why?
|
| Models, Neurological | 3 | 2018 | 24 | 0.220 |
Why?
|
| Arousal | 1 | 2004 | 49 | 0.220 |
Why?
|
| Reaction Time | 5 | 2023 | 95 | 0.210 |
Why?
|
| Time Factors | 2 | 2019 | 1336 | 0.210 |
Why?
|
| Postmenopause | 1 | 2023 | 52 | 0.210 |
Why?
|
| Research Design | 2 | 2021 | 175 | 0.200 |
Why?
|
| Intelligence Tests | 2 | 2015 | 16 | 0.200 |
Why?
|
| Fraud | 1 | 2022 | 18 | 0.200 |
Why?
|
| Psychometrics | 2 | 2021 | 216 | 0.200 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 450 | 0.200 |
Why?
|
| Atherosclerosis | 1 | 2023 | 51 | 0.190 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 294 | 0.190 |
Why?
|
| Geriatric Assessment | 3 | 2017 | 203 | 0.190 |
Why?
|
| Awareness | 1 | 2002 | 38 | 0.190 |
Why?
|
| Facial Expression | 2 | 2012 | 8 | 0.190 |
Why?
|
| Adolescent | 5 | 2021 | 2018 | 0.190 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2023 | 103 | 0.190 |
Why?
|
| Data Interpretation, Statistical | 3 | 2022 | 73 | 0.180 |
Why?
|
| Treatment Outcome | 2 | 2022 | 3204 | 0.180 |
Why?
|
| Emotions | 2 | 2012 | 69 | 0.180 |
Why?
|
| Social Identification | 1 | 2021 | 8 | 0.180 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2021 | 10 | 0.180 |
Why?
|
| Accelerometry | 2 | 2021 | 85 | 0.180 |
Why?
|
| Social Networking | 1 | 2021 | 11 | 0.180 |
Why?
|
| Southeastern United States | 1 | 2020 | 13 | 0.180 |
Why?
|
| Midwestern United States | 1 | 2020 | 40 | 0.170 |
Why?
|
| Organ Size | 3 | 2023 | 91 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 275 | 0.170 |
Why?
|
| Wechsler Scales | 3 | 2006 | 10 | 0.170 |
Why?
|
| Regression Analysis | 4 | 2018 | 251 | 0.170 |
Why?
|
| Acute Disease | 2 | 2012 | 165 | 0.170 |
Why?
|
| Space Perception | 1 | 2020 | 20 | 0.170 |
Why?
|
| Visual Perception | 1 | 2020 | 28 | 0.170 |
Why?
|
| Judgment | 1 | 2019 | 6 | 0.170 |
Why?
|
| Cholesterol, HDL | 1 | 2019 | 26 | 0.160 |
Why?
|
| Disabled Persons | 1 | 2021 | 119 | 0.160 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 29 | 0.160 |
Why?
|
| Patient Selection | 1 | 2021 | 182 | 0.160 |
Why?
|
| Pandemics | 1 | 2021 | 220 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 305 | 0.160 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 267 | 0.160 |
Why?
|
| Interpersonal Relations | 1 | 2020 | 96 | 0.160 |
Why?
|
| Hypercholesterolemia | 1 | 2019 | 20 | 0.160 |
Why?
|
| Atrophy | 2 | 2016 | 88 | 0.160 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 1672 | 0.160 |
Why?
|
| Financing, Personal | 1 | 2018 | 20 | 0.150 |
Why?
|
| Emergencies | 1 | 2019 | 31 | 0.150 |
Why?
|
| Energy Intake | 1 | 2019 | 77 | 0.150 |
Why?
|
| Cognitive Reserve | 1 | 2019 | 38 | 0.150 |
Why?
|
| Genetic Variation | 1 | 2018 | 92 | 0.150 |
Why?
|
| Heterozygote | 1 | 2018 | 91 | 0.150 |
Why?
|
| Healthy Aging | 1 | 2017 | 14 | 0.140 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 45 | 0.140 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2016 | 16 | 0.130 |
Why?
|
| Phobia, Social | 1 | 2016 | 13 | 0.130 |
Why?
|
| Parkinson Disease | 2 | 2020 | 653 | 0.130 |
Why?
|
| Motor Skills | 1 | 2017 | 46 | 0.130 |
Why?
|
| Prognosis | 1 | 2019 | 693 | 0.130 |
Why?
|
| HIV Infections | 1 | 2021 | 452 | 0.130 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 119 | 0.130 |
Why?
|
| Self-Assessment | 2 | 2020 | 29 | 0.130 |
Why?
|
| Gyrus Cinguli | 2 | 2016 | 13 | 0.130 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 171 | 0.130 |
Why?
|
| Urban Population | 1 | 2017 | 147 | 0.130 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 126 | 0.130 |
Why?
|
| Cytokines | 1 | 2017 | 203 | 0.120 |
Why?
|
| Double-Blind Method | 2 | 2012 | 389 | 0.120 |
Why?
|
| Inflammation | 3 | 2023 | 253 | 0.120 |
Why?
|
| Macromolecular Substances | 1 | 2014 | 6 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2014 | 99 | 0.110 |
Why?
|
| Animals | 2 | 2013 | 3430 | 0.110 |
Why?
|
| Axons | 1 | 2013 | 25 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2016 | 229 | 0.110 |
Why?
|
| Oxygen | 1 | 2012 | 64 | 0.100 |
Why?
|
| Autistic Disorder | 1 | 2012 | 39 | 0.100 |
Why?
|
| Language Tests | 2 | 2021 | 32 | 0.100 |
Why?
|
| Reward | 1 | 2011 | 21 | 0.090 |
Why?
|
| Task Performance and Analysis | 1 | 2011 | 47 | 0.090 |
Why?
|
| Social Class | 2 | 2022 | 64 | 0.090 |
Why?
|
| Inositol | 1 | 2011 | 5 | 0.090 |
Why?
|
| Aspartic Acid | 1 | 2011 | 13 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 33 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 567 | 0.090 |
Why?
|
| Syndrome | 1 | 2010 | 73 | 0.080 |
Why?
|
| Weight Loss | 2 | 2023 | 109 | 0.080 |
Why?
|
| Mental Status Schedule | 2 | 2011 | 87 | 0.080 |
Why?
|
| Medicare | 2 | 2019 | 109 | 0.080 |
Why?
|
| Cues | 2 | 2011 | 39 | 0.070 |
Why?
|
| Neuropathology | 2 | 2019 | 75 | 0.070 |
Why?
|
| Comorbidity | 1 | 2009 | 458 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2007 | 45 | 0.070 |
Why?
|
| Functional Laterality | 1 | 2007 | 58 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2011 | 44 | 0.070 |
Why?
|
| Lewy Bodies | 2 | 2019 | 179 | 0.070 |
Why?
|
| Reading | 1 | 2006 | 36 | 0.070 |
Why?
|
| Evoked Potentials | 1 | 2004 | 13 | 0.060 |
Why?
|
| Dominance, Cerebral | 1 | 2004 | 15 | 0.060 |
Why?
|
| Limbic System | 1 | 2004 | 7 | 0.060 |
Why?
|
| Reproduction | 1 | 2023 | 10 | 0.050 |
Why?
|
| Estrogens | 1 | 2023 | 25 | 0.050 |
Why?
|
| Baltimore | 1 | 2003 | 9 | 0.050 |
Why?
|
| Sample Size | 1 | 2003 | 18 | 0.050 |
Why?
|
| Age of Onset | 2 | 2013 | 91 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 47 | 0.050 |
Why?
|
| Infarction | 1 | 2023 | 28 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 30 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 182 | 0.050 |
Why?
|
| Maze Learning | 1 | 2002 | 16 | 0.050 |
Why?
|
| Pregnancy | 1 | 2023 | 298 | 0.050 |
Why?
|
| Boston | 1 | 2022 | 20 | 0.050 |
Why?
|
| Physical Therapy Modalities | 1 | 2022 | 67 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2022 | 9 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 134 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2021 | 12 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2002 | 38 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 31 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 450 | 0.050 |
Why?
|
| Probability | 1 | 2021 | 83 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2021 | 54 | 0.050 |
Why?
|
| Caribbean Region | 1 | 2020 | 3 | 0.040 |
Why?
|
| South America | 1 | 2020 | 3 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2021 | 18 | 0.040 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2020 | 5 | 0.040 |
Why?
|
| Lung | 1 | 2021 | 163 | 0.040 |
Why?
|
| New York | 1 | 2020 | 10 | 0.040 |
Why?
|
| Florida | 1 | 2020 | 17 | 0.040 |
Why?
|
| California | 1 | 2020 | 34 | 0.040 |
Why?
|
| Orientation | 1 | 2020 | 5 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2020 | 25 | 0.040 |
Why?
|
| Walking | 1 | 2022 | 248 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2019 | 12 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 56 | 0.040 |
Why?
|
| Cerebral Ventricles | 1 | 2019 | 17 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2019 | 26 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 318 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 634 | 0.040 |
Why?
|
| Lewy Body Disease | 1 | 2019 | 92 | 0.040 |
Why?
|
| Amyloid | 1 | 2018 | 55 | 0.040 |
Why?
|
| Amygdala | 1 | 2018 | 38 | 0.040 |
Why?
|
| Serial Learning | 1 | 2018 | 7 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 110 | 0.040 |
Why?
|
| Health Status | 1 | 2019 | 214 | 0.040 |
Why?
|
| Perception | 1 | 2018 | 73 | 0.040 |
Why?
|
| Comoros | 1 | 2017 | 1 | 0.040 |
Why?
|
| Neurofibrillary Tangles | 1 | 2018 | 188 | 0.040 |
Why?
|
| Caloric Restriction | 1 | 2017 | 16 | 0.040 |
Why?
|
| Autopsy | 1 | 2018 | 317 | 0.030 |
Why?
|
| Sphygmomanometers | 1 | 2017 | 4 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 46 | 0.030 |
Why?
|
| Massachusetts | 1 | 2017 | 18 | 0.030 |
Why?
|
| tau Proteins | 1 | 2018 | 221 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 73 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 184 | 0.030 |
Why?
|
| Czech Republic | 1 | 2014 | 1 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 28 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 428 | 0.030 |
Why?
|
| Thalamus | 1 | 2014 | 12 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2014 | 32 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2014 | 65 | 0.030 |
Why?
|
| Semantics | 1 | 2014 | 15 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 60 | 0.030 |
Why?
|
| Amino Acids | 1 | 2010 | 19 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2009 | 252 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2011 | 3185 | 0.010 |
Why?
|